IDWeek 2021: Clinical Impact of New Data*

Download All
September 29 - October 3, 2021; Virtual
Get the latest data from IDWeek 2021 on practical management strategies and the latest data for HIV, C difficile, COVID-19, and vaccine-preventable diseases. Explore key studies from this important annual conference in the on-demand webinars, Capsule Summaries, and ClinicalThought expert commentaries. Share the downloadable slidesets with colleagues.
Paul G. Auwaerter, MD
person default
Teena Chopra, MD, MPH
Brenda E. Crabtree Ramírez, MD
Eric S. Daar, MD
Joseph J. Eron, Jr., MD
Kevin Garey, PharmD, MS
Rasika Karnik, MS, MD
Arthur Kim, MD
Karine Lacombe, MD, PhD
Martin C. Mahoney, MD, PhD
Nelly Mugo, MBChB, MMed, MPH
Renslow Sherer, MD
Darcy Wooten, MD

IDWeek 2021: Clinical Impact of New HIV Data

Read expert faculty members’ summaries of key HIV studies from IDWeek 2021, including data on 2-drug ART, metabolic outcomes, investigational agents, long-acting injectable agents, survey data of the U=U educational campaign, premature mortality risk, pneumococcal disease in PWH, maternal DTG use, and PrEP.

Eric S. Daar, MD Joseph J. Eron, Jr., MD Darcy Wooten, MD Released: October 19, 2021

Hear unique insights from expert faculty as she presents updates and new HIV data from IDWeek 2021, including 2-drug ART, metabolic outcomes, investigational agents, and survey data of the U=U educational campaign.

Darcy Wooten, MD Released: October 20, 2021

Hear unique insights from expert faculty as he presents updates and new HIV data from IDWeek 2021, including 2-drug ART, metabolic outcomes, investigational agents, and survey data of the U=U educational campaign.

Eric S. Daar, MD Released: October 21, 2021

Managing weight gain and associated metabolic complications is increasingly important for HIV healthcare professionals. Read my take on the implications of studies in these areas from IDWeek 2021.

Darcy Wooten, MD Released: October 28, 2021

Once perceived as unsafe, during the past 3 years, dolutegravir (DTG) has shifted to being recommended as first-line treatment in women trying to conceive and in those who are pregnant. Read my take on the evolution of our use of DTG in women of child-bearing potential.

Joseph J. Eron, Jr., MD Released: November 18, 2021

New 2-drug regimen strategies for people with HIV have disrupted the traditional treatment paradigm of 3-drug regimens. Read my take on what these data from IDWeek 2021 mean for practice in Western Europe.

Karine Lacombe, MD, PhD Released: November 2, 2021

Gaps in PrEP delivery and uptake remain prevalent. Here’s how we can use information from IDWeek 2021 on evaluation of delivery gaps—and possible solutions—to help us improve PrEP initiation.

Nelly Mugo, MBChB, MMed, MPH Released: October 29, 2021

There is a need for deeper understanding of how 2-drug regimens and metabolic complications affect Latin American PWH given the need for effective ART that does not worsen obesity in a region where this can be prevalent.

Brenda E. Crabtree Ramírez, MD Released: October 28, 2021

Listen to expert insights from Darcy Wooten, MD, on updates and new HIV data from IDWeek 2021, including 2-drug ART, metabolic outcomes, investigational agents, and survey data of the U=U educational campaign.

Darcy Wooten, MD Released: October 11, 2021

IDWeek 2021: Clinical Impact of New Data on C difficile

Studies at IDWeek 2021 show that investigational microbiome-directed therapies are efficacious and positively impact quality of life for patients with recurrent C difficile infection. Here is why I am looking forward to using these therapies in my practice.

person default Teena Chopra, MD, MPH Released: December 23, 2021

Here’s how treatment guidelines are changing prescribing patterns in a way that will hopefully improve patient outcomes and decrease patient burden.

Kevin Garey, PharmD, MS Released: December 17, 2021

IDWeek 2021: Clinical Impact of New COVID-19 Data

Are 28-day outcomes an incomplete assessment of COVID-19? Are potential new approaches improving outpatient and inpatient outcomes? Read our synopsis of new COVID-19 data from IDWeek 2021.

Rasika Karnik, MS, MD Renslow Sherer, MD Released: October 29, 2021

Listen to expert insights from Renslow Sherer, MD, on updates and new COVID-19 data from IDWeek 2021, including prevention, treatment for outpatients and hospitalized patients, and long-term outcomes.

Renslow Sherer, MD Released: October 29, 2021

In this downloadable slideset, CCO’s expert faculty members summarize new data from key studies on COVID-19 presented at this important annual conference.

Arthur Kim, MD Renslow Sherer, MD Released: October 19, 2021

Hear unique insights from expert faculty presenting updates and new COVID-19 data from IDWeek 2021, including prevention, treatment of outpatients and hospitalized patients, and long-term outcomes.

Arthur Kim, MD Released: October 21, 2021

Hear unique insights from expert faculty presenting updates and new COVID-19 data from IDWeek 2021, including prevention, treatment of outpatients and hospitalized patients, and long-term outcomes.

Renslow Sherer, MD Released: October 21, 2021

IDWeek 2021: Clinical Impact of New Data on Vaccine-Preventable Diseases

Studies at IDWeek 2021 show that pneumococcal vaccines with increased serotype valency are safe and efficacious in both children and adults. Here is my take on how these studies could affect my practice and the current vaccination guidelines.

Paul G. Auwaerter, MD Released: November 19, 2021

Listen to expert insights from Martin C. Mahoney, MD, PhD, on new data for vaccine-preventable diseases presented at the IDWeek meeting, including pneumococcal disease, respiratory syncytial virus, herpes zoster, and influenza.

Martin C. Mahoney, MD, PhD Released: December 6, 2021

In this downloadable slideset, CCO’s expert faculty summarizes important studies from IDWeek 2021, including new data on vaccines for pneumococcal disease, respiratory syncytial virus, herpes zoster, and influenza.

Martin C. Mahoney, MD, PhD Released: November 3, 2021

Hear unique insights from expert faculty on important studies from IDWeek 2021, including new data on vaccines for pneumococcal disease, respiratory syncytial virus, herpes zoster, and influenza.

Martin C. Mahoney, MD, PhD Released: November 11, 2021

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings